Bank of New York Mellon’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-224,805
| Closed | -$7.74M | – | 4298 |
|
|
2020
Q3 | $7.74M | Sell |
224,805
-7,664
| -3% | -$163K | ﹤0.01% | 1984 |
|
|
2020
Q2 | $3.88M | Buy |
232,469
+1,049
| +0.5% | +$17.8K | ﹤0.01% | 2341 |
|
|
2020
Q1 | $3.34M | Sell |
231,420
-431,739
| -65% | -$11M | ﹤0.01% | 2285 |
|
|
2019
Q4 | $22.2M | Sell |
663,159
-320,595
| -33% | -$8.96M | 0.01% | 1510 |
|
|
2019
Q3 | $20.6M | Buy |
983,754
+626,787
| +176% | +$12.8M | 0.01% | 1516 |
|
|
2019
Q2 | $7.43M | Buy |
356,967
+151,639
| +74% | +$3.12M | ﹤0.01% | 2132 |
|
|
2019
Q1 | $4.59M | Sell |
205,328
-347,878
| -63% | -$8.19M | ﹤0.01% | 2369 |
|
|
2018
Q4 | $13.2M | Buy |
553,206
+382,154
| +223% | +$9.89M | ﹤0.01% | 1754 |
|
|
2018
Q3 | $4.67M | Sell |
171,052
-714
| -0.4% | -$20.2K | ﹤0.01% | 2439 |
|
|
2018
Q2 | $4.62M | Buy |
171,766
+14,283
| +9% | +$437K | ﹤0.01% | 2438 |
|
|
2018
Q1 | $5.01M | Buy |
157,483
+23,898
| +18% | +$841K | ﹤0.01% | 2360 |
|
|
2017
Q4 | $5.05M | Sell |
133,585
-1,029
| -0.8% | -$33.2K | ﹤0.01% | 2360 |
|
|
2017
Q3 | $3.34M | Buy |
134,614
+3,261
| +2% | +$70.3K | ﹤0.01% | 2534 |
|
|
2017
Q2 | $2.7M | Buy |
131,353
+19,016
| +17% | +$363K | ﹤0.01% | 2665 |
|
|
2017
Q1 | $2.44M | Sell |
112,337
-23,901
| -18% | -$490K | ﹤0.01% | 2726 |
|
|
2016
Q4 | $2.79M | Buy |
136,238
+45,575
| +50% | +$932K | ﹤0.01% | 2656 |
|
|
2016
Q3 | $1.36M | Buy |
90,663
+8,002
| +10% | +$108K | ﹤0.01% | 3007 |
|
|
2016
Q2 | $895K | Buy |
82,661
+31,245
| +61% | +$425K | ﹤0.01% | 3215 |
|
|
2016
Q1 | $697K | Buy |
51,416
+6,867
| +15% | +$107K | ﹤0.01% | 3270 |
|
|
2015
Q4 | $822K | Buy |
44,549
+18,206
| +69% | +$337K | ﹤0.01% | 3290 |
|
|
2015
Q3 | $667K | Buy |
+26,343
| New | +$616K | ﹤0.01% | 3430 |
|
Bank of New York Mellon's AIMT Position: Q4 2020 in Review
Bank of New York Mellon sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 224,805 shares — an estimated $7.74M sold.
Bank of New York Mellon first reported a position in AIMT in Q3 2015 and held it in 21 quarters. The position peaked at $22.2M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Bank of New York Mellon reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Bank of New York Mellon sold 224,805 Aimmune Therapeutics shares in Q4 2020, an estimated $7.74M.
- Bank of New York Mellon first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 21 quarters.
- Bank of New York Mellon's Aimmune Therapeutics position peaked at $22.2M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Bank of New York Mellon's 13F filing for Q4 2020, filed 9 Feb 2021.